2. Academic Validation
  3. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections

  • J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.
Thomas V Magee 1,  Sharon L Ripp,  Bryan Li,  Richard A Buzon,  Lou Chupak,  Thomas J Dougherty,  Steven M Finegan,  Dennis Girard,  Anne E Hagen,  Michael J Falcone,  Kathleen A Farley,  Karl Granskog,  Joel R Hardink,  Michael D Huband,  Barbara J Kamicker,  Takushi Kaneko,  Michael J Knickerbocker,  Jennifer L Liras,  Andrea Marra,  Ivy Medina,  Thuy-Trinh Nguyen,  Mark C Noe,  R Scott Obach,  John P O'Donnell,  Joseph B Penzien,  Usa Datta Reilly,  John R Schafer,  Yue Shen,  Gregory G Stone,  Timothy J Strelevitz,  Jianmin Sun,  Amelia Tait-Kamradt,  Alfin D N Vaz,  David A Whipple,  Daniel W Widlicka,  Donn G Wishka,  Joanna P Wolkowski,  Mark E Flanagan
Affiliations

Affiliation

  • 1 Pfizer Global Research & Development, Pfizer, Inc, Groton, Connecticut 06340, USA.
PMID: 19775168 DOI: 10.1021/jm900729s
Abstract

Respiratory tract Bacterial strains are becoming increasingly resistant to currently marketed Macrolide Antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

Figures
Products